Stereochemistry | ABSOLUTE |
Molecular Formula | C21H31N3O5 |
Molecular Weight | 405.4879 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCCC[C@H](N[C@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O
InChI
InChIKey=RLAWWYSOJDYHDC-KSZLIROESA-N
InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17+,18-/m0/s1
Molecular Formula | C21H31N3O5 |
Molecular Weight | 405.4879 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
(R)-Lisinopril Sodium Salt is the R,S,S-Isomer of Lisinopril. Lisinopril is a potent inhibitor of angiotensin-converting enzyme (ACE). Lisinopril prevents the conversion of angiotensin I to angiotensin II, which acts as a potent vasoconstrictor and also signals the release of aldosterone, which modulates sodium absorption. ACE inhibition has the net result of vasodilation and increased sodium and water excretion. Lisinopril, (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]
hexanoyl]pyrrole-2-carboxylic acid is an angiotensin-converting
enzyme (ACE) inhibitor, used for the treatment of hypertension,
heartfailure andacutemyocardial infarction. The
RSS isomer of lisinopril ((2S)-1-[(2S)-6-amino-2-[[(1R)-1-carboxy-
3-phenylpropyl]amino]hexanoyl]pyrrole-2-carboxylic acid) is an
impurity (impurity E) resulting from the synthesis of lisinopril. The impurity profile of a drug substance is critical to its safety
assessment and is important for monitoring the manufacturing
process.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|